Autopsy report · NCT00472433

The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias

“no eligible patient”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 2 years 2 months before it stopped.
• 30 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Phramongkutklao College of Medicine and Hospital

Sponsor type

University, hospital or other

Conditions

Autoimmune Cytopenias

Interventions

Alemtuzumab

Participants

30 (planned, not actual)

Sites

1

Countries

Thailand

Trials that died the same way

• Hepatitis C in Prison: Study of Screening and Rapid Treatment (HEPAPRIS)
  “No patient eligible” (98% match in meaning)
• The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study
  “Lack of eligible patients” (83% match in meaning)
• Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
  “Not enough eligible patients available” (83% match in meaning)
• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (82% match in meaning)
• QLESP Block in Hip Surgery
  “No patients enrolled” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.